What is it about?
Surgery aiming for complete tumor resection (R0) remains the cornerstone of the treatment for HBP cancers. The current progress in the adjuvant treatment is quite slow, with gemcitabine chemotherapy available only for pancreatic ductal adenocarcinoma (PDA).
Featured Image
Why is it important?
These advances dictate new designs for clinical trials to validate biomarkers and drugs. This review discusses the findings of available NGS studies on HBP cancers and the limitations of genome sequencing analysis to translate genome-based biomarkers and drugs into patient care in the clinic.
Perspectives
Breakthrough methods of NGS applications, including multi-regional biopsies for genome sequencing to identify ITH and repeated NGS of plasma circulating cell-free DNA or circulating tumor DNA (cfDNA, ctDNA) can identify dynamic emergence of distinct subclones. By comparing the GA landscape of the primary tumor to that of circulating genomic subclones (CGS) and the relapsed tumors in individual patients, we could develop biomarkers to predict and monitor disease relapse. Furthermore, an early targeting of the identified resistant subclones could overcome therapeutic resistance, prolonging time to recurrence or even preventing metastatic relapse.
Dr Demosthenes E. Ziogas
Peripheral General Hospital of Ioannina - Xatzikosta
Read the Original
This page is a summary of: From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers, International Journal of Molecular Sciences, January 2017, MDPI AG,
DOI: 10.3390/ijms18010180.
You can read the full text:
Contributors
The following have contributed to this page
